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Effective immunity requires that a limitedTCR repertoire is able to recognize a vast number
of foreign peptide-MHCI (peptide-major histocompatibility complex class I) molecules.This
challenge is overcome by the ability of individual TCRs to recognize large numbers of pep-
tides. Recently, it was demonstrated that MHCI-restricted TCRs can recognize up to 106
peptides of a defined length. Astonishingly, this remarkable level of promiscuity does not
extend to peptides of different lengths, a fundamental observation that has broad implica-
tions for CD8+ T-cell immunity. In particular, the findings suggest that effective immunity
can only be achieved by mobilization of “length-matched” CD8+ T-cell clonotypes. Overall,
recent findings suggest that everyTCR is specific for a unique set of peptides, which can be
described as a unique “peptide recognition signature” (PRS) and consists of three compo-
nents: (1) peptide length preference, (2) number of peptides recognized; and, (3) sequence
identity (e.g., self versus pathogen derived). In future, the ability to de-convolute peptide
recognition signatures across the normal and pathogenic repertoire will be essential for
understanding the system requirements for effective CD8+T-cell immunity and elucidating
mechanisms which underlie CD8+ T-cell mediated disease.
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INTRODUCTION
CD8+ T cells are important for the control of viral infection and
the natural eradication of cancer. CD8+ T cells recognize short
peptides presented at the target cell surface bound to major histo-
compatibility complex class I (MHCI) molecules (1). Recognition
of peptide-MHCI (pMHCI) is mediated by the alpha beta T-cell
receptor (TCR). Initially, it was thought that MHCI molecules pre-
dominantly presented peptides of between 8 and 10 amino acids in
length. However, subsequent studies demonstrated that peptides
of between 11 and 14 amino acids in length are also presented and
can be highly immunogenic (2). In fact, many longer peptides can
be immunodominant over completely overlapping shorter pep-
tides that also bind to the same MHCI allele (3–6). Thus, it is
now well established that MHCI can present peptides of between
8 and 14 amino acids in length. A vast array of peptides within this
length range can be generated from permutations of the twenty
proteogenic l-amino acids (1.7× 1018). Of course, not all of these
peptide sequences occur in the current database of natural pro-
teins. However, it is vital that the TCR repertoire is poised to rec-
ognize vast numbers of peptide sequences, even if not identified to
date, in order to adapt and deal with changes in pathogen diversity.
The MHCI-presented peptide repertoire is constrained by fac-
tors such as the specificity of antigen processing pathway com-
ponents (proteasome, ERAAP/ERAP1, tapasin, and TAP) and the
HLA type of the individual (7,8). As a result, conservative estimates
suggest that only ∼1% of the peptide universe can be processed
and presented at the cell surface in the context of MHCI (9). How-
ever, this still leaves a staggering 1.7× 1016 peptides of different
lengths to which a relatively small number of TCRs (∼25 mil-
lion) (10) must be able to respond appropriately. Therefore, in
order to understand the requirements for effective CD8+ T-cell
immunity, it is important to understand how a limited TCR reper-
toire responds and adapts to the vast number of possible different
epitopes across a length spectrum.
INDIVIDUAL TCRs CAN RECOGNIZE LARGE NUMBERS OF
PEPTIDES OF A DEFINED LENGTH
It has been appreciated for many years that individual TCRs can
recognize multiple ligands (11–18). Initial studies of TCR degen-
eracy were conducted using small numbers of peptide analogs
(typically less than 200). The development of combinatorial pep-
tide library (CPL) screening which was pioneered by Houghten
et al. (19, 20) allowed for a more comprehensive analysis of TCR
degeneracy and the ability to define much larger numbers of candi-
date peptide analogs (21). A more recent study examined ∼4,000
peptides, although it must be appreciated that this number still
only represents an extremely small portion of the entire peptide
universe (18).
Estimates of TCR degeneracy were initially performed using
data from peptide library screening. Elegant studies which were
conducted by two independent groups estimated that individual
MHCII-restricted TCRs can recognize ∼106 peptides (22, 23). A
similar analysis performed by Wilson and colleagues suggested
that MHCI-restricted TCRs exhibit lower levels of degeneracy
(24). However, approaches performed using small peptide sets or
library screening alone preclude a comprehensive analysis of the
entire peptide universe and as such, may result in an underestimate
of TCR degeneracy. In order to address this possibility, a recent
study developed an approach to quantify TCR degeneracy that can
be used to probe the entire peptide universe of a defined length.
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This approach involves a combination of sampling from motif-
restricted peptide sets and sampling from the entire peptide uni-
verse with bias toward those peptides predicted to elicit a response
(termed CPL-based importance sampling) (25). The approach was
used to construct a degeneracy curve which revealed, in the initial
application of this strategy, that an individual MHCI-restricted
TCR (1E6) can recognize over one million different decamer pep-
tides in the context of a single MHCI at physiologically relevant
concentrations. Furthermore, it was possible to identify peptides
that were up to 100-fold more potent than the cognate peptide
for this particular TCR. To date, this study represents the most
comprehensive quantification of MHCI-restricted TCR degen-
eracy (25). However, continued development of techniques that
allow rapid and accurate quantification of TCR degeneracy are
essential if we are to understand the role that this phenomenon
plays in common T-cell mediated diseases.
The ability of individual TCRs to recognize large numbers of
peptides provides an explanation for how a limited TCR reper-
toire can provide effective immune coverage against all possible
foreign pMHCI that can be encountered. However this analysis
was confined to a single autoimmune TCR which may repre-
sent the extreme end of the cross-reactivity spectrum. In order
to understand the system requirements for effective CD8+ T-cell
immunity, it will be important to measure how this phenomenon
varies across the normal TCR repertoire. It is tempting to speculate
that variations in levels of TCR degeneracy may contribute to the
pathogenesis of disease. In fact there is emerging evidence to sug-
gest that this is indeed the case. For example, several studies suggest
that levels of TCR degeneracy can influence disease outcome dur-
ing infection with viruses such as HIV-1 that have a high mutation
rate (26–29). Overall more information is required about how
TCR degeneracy varies across the normal TCR repertoire and the
role that variations play in the pathogenesis of disease.
TCRs EXHIBIT AN EXPLICIT PREFERENCE FOR MHCI-BOUND
PEPTIDE LENGTH
It is clear that TCRs can recognize a large number of peptides
of a defined length and it would seem logical that this flexibility
could extend to the recognition of peptides of different lengths, as
this would maximize the ability of the TCR repertoire to provide
broad antigenic coverage. In order to examine this possibility, a
recent study utilized a series of combinatorial peptide libraries,
ranging from 8 to 13 amino acids in length, to perform a com-
prehensive analysis of peptide length preference across a panel
of CD8+ T-cell clones raised against a range of pMHCI anti-
gens spanning different peptide lengths derived from both foreign
and self antigens (30). An unexpected feature of the TCR/pMHCI
interaction was discovered by showing that any given TCR exhibits
an explicit preference for a single MHCI-bound peptide length
(30). This MHCI-bound peptide length preference was identi-
cal to the length of the original peptide which had been used to
derive each clone. Furthermore, this unexpected finding applied
to all TCRs examined regardless of antigenic specificity and MHCI
restriction. Importantly, peptide length preference was shown to
be an intrinsic feature of the TCR and not determined by differ-
ential MHCI-peptide binding. A very small number of agonists
of non-preferred length were identified, but the incidence of this
phenomenon was extremely rare and recognition was generally
sub-optimal when compared to peptides of the preferred length.
Interestingly, however, agonists of non-preferred length identified
were entirely distinct in sequence, with a different amino acid
residue at every position. As described above, CPL-based impor-
tance sampling revealed that the 1E6 TCR can recognize over one
million different 10mer peptides at a functional sensitivity equiva-
lent to or greater than index (25). In contrast, the 1E6 TCR was not
capable of recognizing any 8, 9, 11, 12, or 13mer peptides within
this functional sensitivity range. Thus, individual MHCI-restricted
TCRs exhibit an explicit preference for a single MHCI-peptide
length (30). The next challenge will be to explain how a repertoire
of TCRs that display a stringent preference for peptide length can
provide effective immune coverage against all peptide lengths that
can be presented by MHCI. To address this question, it will be
important to examine how peptide length preference varies across
the entire TCR repertoire.
IMPLICATIONS OF MHCI-BOUND PEPTIDE LENGTH
PREFERENCE FOR CD8+ T-CELL IMMUNITY
The TCR/pMHCI interaction is pivotal in all aspects of CD8+
T-cell immunity including thymic development, naive T-cell sur-
vival, and recognition of foreign pMHCI in the periphery. Peptide
length determines the outcome of TCR/pMHCI engagement and,
as such, has far-reaching implications (Box 1). Firstly, the findings
predict that the thymic epithelial cell (TEC) (31, 32) surface must
display peptides of multiple different lengths to ensure that an
appropriately diverse CD8+ T-cell repertoire undergoes positive
and negative selection before being released into the periphery.
Once in the periphery, continual TCR engagement of low affinity
self-derived pMHCI molecules is essential for naive T-cell survival
(33, 34). Here, peptides of non-preferred length may actually play
a very important role because signaling below the threshold for T-
cell activation may be sufficient for the delivery of survival signals.
Box 1 Implications of peptide length preference.
A: Implications for CD8+ T-cell immunity
• Thymic development: TECs must display peptides of multiple
lengths
• Naive T-cell survival: mediated by recognition of defined length
peptides
• Effective CD8+ T-cell immunity: requires “length-matched”
clonotypes
• Protective vaccination: must elicit “length-matched” clono-
types
B: Implications for disease pathogenesis
• Identification of ligands that trigger CD8+ T-cell expansions in
autoimmunity and hematological disease: length preference
must be established
• Rare peptides of non-preferred length peptides with entirely dis-
parate sequence: may represent a novel mechanism underlying
molecular mimicry
• Alloreactivity: an important consideration in the identification of
alloreactive ligands
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Importantly, the findings imply that the CD8+ T-cell repertoire
is compartmentalized with respect to peptide length preference,
such that effective immunity can only be achieved by mobiliza-
tion of the appropriate “length-matched” antigen-specific CD8+
T-cell clonotypes (30). To understand the system requirements
for effective CD8+ T-cell immunity, it will therefore be necessary
to examine how peptide length preference varies across the nor-
mal TCR repertoire and how different “peptide length footprints”
overlap to provide effective coverage across all peptide lengths. The
length preference phenomenon also informs our understanding of
the requirements for effective peptide vaccination. For example, it
was recently observed that the heteroclitic 10mer epitope ELAGIG-
ILTV derived from MART-1/Melan-A, which is commonly used in
melanoma clinical trials, primes a population of CD8+ T cells that
is very poor at cross-recognizing the dominant naturally presented
9mer epitope AAGIGILTV (35, 36). These findings may explain,
at least in part, the poor objective response rates observed in these
trials (37). Accordingly, such findings suggest that peptide length is
likely to be an important consideration in the provision of effective
CD8+ T-cell immunity and the response to peptide vaccination.
IMPLICATIONS OF MHCI-BOUND PEPTIDE LENGTH
PREFERENCE FOR DISEASE PATHOGENESIS
As well as playing a critical role in CD8+ T-cell immunity, the
TCR/pMHCI interaction can result in inappropriate CD8+ T-
cell activity in situations such as autoimmunity, hematological
disorders, and transplant rejection (alloreactivity). Factors that
influence the outcome of TCR/pMHCI engagement, such as pep-
tide length, therefore impact on our understanding of disease
pathogenesis. Transient, asymptomatic CD8+ T-cell expansions
are relatively common and often associated with viral infections.
However, in certain disease states, monoclonal/oligoclonal CD8+
T-cell expansions with a differentiated phenotype persist, sug-
gesting an exaggerated response to an immunodominant antigen.
Monoclonal CD8+ T-cell expansions are a characteristic feature
of T-LGL leukemia (38), but can also be triggered by drugs [e.g.,
protein tyrosine kinase inhibitors (39)]. Oligoclonal expansions
have been observed in various autoimmune diseases [e.g., multiple
sclerosis (40, 41), rheumatoid arthritis (42), and aplastic anemia
(43)]. To date, there has been no attempt to identify the origin
of the ligands that drive these potentially pathogenic CD8+ T-
cell populations. This is a priority for the future because it will
yield information about the pathogenesis of these important dis-
eases. In order to achieve this goal, the dominant pathogenic
T-cell clone must be isolated and the peptide length preference
defined. This will narrow the search and allow the selection of
length-appropriate peptide libraries to enable ligand hunting.
Alloreactivity represents a major barrier to transplantation and,
as such, there is a pressing need to understand the molecular and
structural basis of this phenomenon (44, 45). This is especially
important considering that substantial efforts are being made to
increase the number of available donors despite the fact that, in
the last decade, little progress has been made in understanding
how to reduce the risks and severity of transplant rejection. It
is well established that alloreactive T-cells are highly prevalent
within the T-cell repertoire. However, the mechanisms that under-
lie this phenomenon remain unclear. Originally, it was thought
that alloreactivity was mediated by TCR recognition of foreign
MHC (“MHC-centric”). More recently, however, it has become
increasingly apparent that the alloreactive TCR/pMHCI interac-
tion can be highly peptide-dependent (“peptide-centric”) (46–48).
In fact, it appears that peptide specificity is profound when self-
MHCI and foreign-MHCI are closely related (49). Further stud-
ies are required to determine whether alloreactive TCR/pMHCI
interactions exhibit the levels of promiscuity that typify autol-
ogous TCR/pMHCI interactions. It will also be important to
examine the possibility that alloreactive TCR/pMHCI interactions
may exhibit a peptide length preference. This will facilitate the
identification of alloreactive ligands and allow characterization
of the peptide repertoire recognized in the context of non-self
MHCI (30).
INDIVIDUAL MHCI-RESTRICTED TCRs ARE CHARACTERIZED
BY A UNIQUE PEPTIDE RECOGNITION SIGNATURE
Taken together, recent observations suggest that every TCR is spe-
cific for a unique set of peptides,which can be described as a unique
“peptide recognition signature”(PRS) (Figure 1). The PRS of indi-
vidual TCRs comprises three different components: (i) an explicit
preference for a single MHCI-peptide length; (ii) the number of
peptide sequences recognized at the preferred length, which can be
very large (up to ∼106 different peptides); and, (iii) the sequence
identity of the recognized peptides, many of which will be biologi-
cally relevant. The sequence identity of the peptides recognized by
an individual TCR is the most important component of the PRS
(Figure 1). Many of the peptide sequences recognized by individ-
ual TCRs can appear in a large number of self proteins or pathogen
derived proteins. If these sequences can be naturally processed and
presented at the cell surface then the TCR will have the opportu-
nity to mount a response to them in vivo. If a TCR can respond to
naturally processed sequences from more than one pathogen then
this will allow a single TCR to provide immunity to more than one
infection. This phenomenon [often referred to as “heterologous
immunity” (50, 51)] is extremely important for the provision of
effective immunity and an example of the immense benefits that
can be gained from TCR degeneracy. However, the ability to be
able to recognize both self and pathogen derived pMHCI has the
potential to be highly pathogenic and provides a mechanistic basis
for “molecular mimicry,” which is the widely hypothesized cause
of autoimmune disease (52). Although good examples of molec-
ular mimicry exist in mouse models of disease there is still a lack
of concrete evidence for this in human autoimmune disease (52).
It is very important that this question is answered in the context
of human disease. The ability to de-convolute the PRS of TCRs
involved in autoimmune disease will be of immense interest in the
future.
APPROACHES THAT CAN BE USED TO DE-CONVOLUTE THE
PRS OF INDIVIDUAL TCRs
CD8+ T cells play a major role in the pathogenesis of autoimmu-
nity, hematological disease, and transplant rejection, as described
above. In the future, the ability to de-convolute the PRS of path-
ogenically relevant TCRs will allow us to dissect the underlying
mechanisms of common CD8+ T-cell mediated disease. This
information can then be used to inform the rational design of
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FIGURE 1 |The peptide recognition signature of everyTCR consists of
three components. The figure depicts the three components of the
peptide recognition signature. One: peptide length preference: this finding
implies that effective CD8+ T-cell immunity can only be achieved if
“length-matched” antigen-specific CD8+ T-cell clonotypes are mobilized
during an immune response, two: number of peptides recognized at the
preferred peptide length: which can be very large (up to ∼106). The ability
of individual TCRs to recognize multiple pMHCI is essential for the
provision of effective immune coverage against the multitude of foreign
pMHCI that can be encountered, and; three: sequence of the recognized
peptides (which dictates the biological relevance of the peptide
recognition signature): the ability to be able to recognize both pathogen
and self-derived pMHCI could be the basis for “molecular mimicry,” which
is the widely hypothesized cause of autoimmune disease. Evidence for
this phenomenon exists in animal models of autoimmunity but convincing
data in human disease is still lacking. By way of an example, the figure
depicts the ability of the same TCR to recognize peptide sequences
generated from both environmental pathogens and oligodendrocytes.
Alternatively, if a TCR can respond to naturally processed and presented
peptide sequences from more than one pathogen then this will allow a
single TCR to provide immunity to more than one infection. It has been
suggested that this phenomenon (often referred to as “heterologous
immunity”) is extremely important for the provision of effective immunity.
By way of an example, the figure depicts the ability of the same TCR to
recognize naturally processed and presented peptide sequences from two
different viruses.
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novel therapeutic strategies. As such there is a pressing need to
design approaches that can be used to achieve this goal. There
have been some elegant attempts to develop an approach that
allows the identification of ligands recognized by CD8+ T-cell
populations of potential pathogenic significance (15, 53, 54). How-
ever, an appreciation that every TCR is characterized by a unique
PRS will facilitate this analysis. Firstly, it will be necessary to define
the peptide length preference of the individual TCR of interest
so that appropriate ligand hunting tools can be selected, such as
length-matched peptide libraries. Secondly, the number of pep-
tides that can be recognized by the individual TCR may influence
the approach that is being used. For example, highly cross-reactive
TCRs will be more challenging than those that exhibit a more
focused phenotype. And finally, tools to identify the origin of the
peptide sequences (i.e., pathogen versus self protein) will be essen-
tial. Emphasis should be placed on developing an approach that is
rapid and can be scaled up to allow the analysis of large numbers
of TCRs in a short space of time. If this can be achieved, then
the ability to de-convolute PRSs across the normal and diseased
repertoire is expected to yield large but very important databases
of information for the future.
CONCLUDING REMARKS
In summary, based on recently generated data, I suggest that
every TCR in the naive repertoire is characterized by a unique
PRS; all of which overlap to provide effective immune coverage
against all possible foreign-MHCI-bound peptides that could be
encountered. A comprehensive study to examine how the PRS
of individual TCRs varies across the normal TCR repertoire will
allow us to determine how a relatively limited number of TCRs can
recognize the multitude of 8–14 amino acid length peptides that
can be encountered in complex with MHCI, and thereby define
the system requirements for effective CD8+ T-cell immunity. In
addition, approaches that can be used to de-convolute the PRSs of
individual pathogenically relevant TCRs are essential if we are to
gain an understanding of the mechanisms that underlie common
CD8+ T-cell mediated diseases.
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